These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

420 related items for PubMed ID: 30151728

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. DPP-4 inhibitors and cardiovascular disease in type 2 diabetes mellitus. Expectations, observations and perspectives.
    Bonora E, Cigolini M.
    Nutr Metab Cardiovasc Dis; 2016 Apr; 26(4):273-84. PubMed ID: 27038847
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
    Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I, SAVOR-TIMI 53 Steering Committee and Investigators.
    N Engl J Med; 2013 Oct 03; 369(14):1317-26. PubMed ID: 23992601
    [Abstract] [Full Text] [Related]

  • 35. Type 2 diabetes and cardiovascular prevention: the dogmas disputed.
    Giugliano D, Maiorino MI, Bellastella G, Esposito K.
    Endocrine; 2018 May 03; 60(2):224-228. PubMed ID: 28895030
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. [Outcome studies on SGLT-2 inhibitors].
    Seufert J, Laubner K.
    Internist (Berl); 2019 Sep 03; 60(9):903-911. PubMed ID: 31375850
    [Abstract] [Full Text] [Related]

  • 38. Glucagon and heart in type 2 diabetes: new perspectives.
    Ceriello A, Genovese S, Mannucci E, Gronda E.
    Cardiovasc Diabetol; 2016 Aug 27; 15(1):123. PubMed ID: 27568179
    [Abstract] [Full Text] [Related]

  • 39. Glucose-Lowering Medications and Cardiovascular Outcomes.
    Shanmugasundaram M, Pineda JRE, Murugapandian S.
    Curr Cardiol Rep; 2021 Mar 02; 23(4):24. PubMed ID: 33655453
    [Abstract] [Full Text] [Related]

  • 40. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, Husain M, Cherney DZ.
    Circulation; 2016 Sep 06; 134(10):752-72. PubMed ID: 27470878
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.